^
    1d
    GEM-IBERDARAX: Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, PETHEMA Foundation | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab) • dexamethasone • iberdomide (CC-220)
    3d
    Throat pack: Soaked Pharyngeal Packing Agents in Septoplasty (clinicaltrials.gov)
    P3, N=65, Completed, Assiut University | Recruiting --> Completed
    Trial completion
    |
    dexamethasone
    3d
    Hemophagocytic lymphohistiocytosis: new grading classification and targeted therapies. (PubMed, Clin Adv Hematol Oncol)
    Although etoposide with dexamethasone remains the most frequently used first-line regimen, various new therapies are now being employed in the management of HLH. The interferon gamma inhibitor emapalumab, the Janus kinase signal transducer and activator of transcription pathway inhibitor ruxolitinib, and the interleukin 6 (IL-6) inhibitor tocilizumab have been trialed in HLH management, with additional treatment options being inhibition of IL-18 and tumor necrosis factor alpha. Here, we summarize current management options for HLH; we also propose a new grading system for HLH based on Common Terminology Criteria for Adverse Events version 5.0 as well as on known prognostic factors (eg, abnormal bilirubin and transaminase levels, elevated creatinine level, respiratory failure, neutropenia, hypertriglyceridemia, hypoalbuminemia, and coagulopathy), which could standardize the diagnosis and guide prompt and appropriate management.
    Review • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18)
    |
    Jakafi (ruxolitinib) • etoposide IV • dexamethasone • Actemra IV (tocilizumab)
    3d
    Sphenopalatine Ganglion Block as Adjuvant to General Anesthesia Regarding the Quality of Surgical Field in Trans-Sphenoidal Endoscopic Hypophysectomy (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Cairo University
    New trial
    |
    dexamethasone
    3d
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1/2, N=208, Active, not recruiting, GlaxoSmithKline | Phase classification: P2 --> P1/2
    Phase classification
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    3d
    A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) (clinicaltrials.gov)
    P2/3, N=340, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    Blincyto (blinatumomab) • dexamethasone • Actemra IV (tocilizumab) • Sylvant (siltuximab)
    3d
    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2/3, N=501, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone
    3d
    MEDOPP0776: PHASE?IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study) (2025-524613-89-00)
    P1/2, N=129, Not yet recruiting, Medica Scientia Innovation Research S.L.
    New P1/2 trial
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • Halaven (eribulin mesylate) • Tukysa (tucatinib) • dexamethasone • Ziihera (zanidatamab-hrii)
    3d
    A Clinical Trial of OM336 to Help Immunized Patients Become Eligible for Kidney Transplantation (2025-523222-40-00)
    P1/2, N=6, Medical University Of Vienna
    New P1/2 trial
    |
    dexamethasone • valacyclovir
    4d
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=260, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • TQB2934
    4d
    Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (clinicaltrials.gov)
    P1/2, N=26, Not yet recruiting, Seoul National University Hospital | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial primary completion date
    |
    dexamethasone • dexamethasone injection
    4d
    A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone